Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.

The German conglomerate announced a licensing agreement with Puhe BioPharma for a PRMT5 inhibitor used in a variety of ...

Makary earlier this month distanced himself from the recent shake-ups at the FDA, including the cancellation of its vaccines ...

WVE-N531, an oligonucleotide, elicited significant functional benefit and reversal of muscle damage in the Phase II ...

Eli Lilly and Novo Nordisk are in a global battle for dominance in the weight loss space. BioSpace takes a look at the ...

Trump's proposed tariffs on the EU would increase manufacturing costs for pharma companies and would stall medical innovation ...

There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

President Donald Trump’s tariffs on pharmaceuticals "to come at some point" as companies promise to build infrastructure in ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...